Citations 10

Glial Fibrillary Acidic Protein in Multiple System Atrophy (P10-7.003)

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217890

Whole tissue proteomic analyses of cardiac ATTR and AL unveil mechanisms of tissue damage

Amyloid | January 8, 2025 | Volume: 32 | Issue: 1 | Pages: 72-80

10.1080/13506129.2024.2448440 | PMID 39773246

Blood-Based Nanoparticle-Enhanced Quaking-Induced Conversion (Nano-QuIC): Inhibitor-Resistant Detection of Seeding Activity in Patients Diagnosed with Parkinson’s Disease

Nano Letters | November 1, 2024 | Volume: 24 | Issue: 47 | Pages: 15016-15024

10.1021/acs.nanolett.4c03768 | PMID 39485864

Alpha-Synuclein Oligomers and Neurofilament Light Chain Predict Phenoconversion of Pure Autonomic Failure (S30.002)

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.3601

Systemic misfolding of immunoglobulins in the test tube and in the cell

The FASEB Journal | June 21, 2021 | Volume: 32 | Issue: S1 | Pages: No page available

10.1096/fasebj.2018.32.1_supplement.247.3

Alpha‐Synuclein Oligomers and Neurofilament Light Chain Predict Phenoconversion of Pure Autonomic Failure

Annals of Neurology | April 22, 2021 | Volume: 89 | Issue: 6 | Pages: 1212-1220

10.1002/ana.26089 | PMID 33881777

Objective To explore the role of alpha‐synuclein (αSyn) oligomers and neurofilament light chain (NfL) in cerebrospinal fluid (CSF) of patients with pure autonomic failure (PAF) as markers of future phenoconversion to multiple system atrophy (MSA). Methods Well‐characterized patients with PAF (n = 32) were enrolled between June 2016 and February 2019 at Mayo Clinic Rochester and followed prospectively with annual visits to determine future phenoconversion to MSA, Parkinson's disease (PD), or dementia with Lewy bodies (DLB). ELISA was utilized to measure NfL and protein misfolding cyclic amplification (PMCA) to detect αSyn oligomers in CSF collected at baseline. Results Patients were followed for a median of 3.9 years. Five patients converted to MSA, 2 to PD, and 2 to DLB. NfL at baseline was elevated only in patients who later developed MSA, perfectly separating those from future PD and DLB converters as well as non‐converters. ASyn‐PMCA was positive in all but two cases (94%). The PMCA reaction was markedly different in five samples with maximum fluorescence and reaction kinetics previously described in MSA patients; all of these patients later developed MSA. Interpretation αSyn‐PMCA is almost invariably positive in the CSF of patients with PAF establishing this condition as α‐synucleinopathy. Both NfL and the magnitude and reaction kinetics of αSyn PMCA faithfully predict which PAF patients will eventually phenoconvert to MSA. This finding has important implications not only for prognostication, but also for future trials of disease modifying therapies, allowing for differentiation of MSA from Lewy body synucleinopathies before motor symptoms develop. ANN NEUROL 2021;89:1212–1220
Early events in light chain aggregation at physiological pH reveal new insights on assembly, stability, and aggregate dissociation

Amyloid | February 4, 2021 | Volume: 28 | Issue: 2 | Pages: 113-124

10.1080/13506129.2021.1877129 | PMID 33533277

Urinary extracellular vesicle analysis and detection of low abundance immunoglobulin oligomers in samples isolated from patients with significant urine proteinuria

No container title available | September 4, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.13477/v1

Abstract Urinary extracellular vesicles (uEVs) have been used as a biomarker tool for detection of low abundance immunoglobulin-based targets in uEVs with heterogeneous high protein mixtures. This protocol outlines a pre-incubation method to minimize non-specific secondary antibody binding. Additionally, we include our approach for standardization of uEV amounts used for sample comparison. We propose that these and knowledge of the detection limit for target proteins are strategies applicable to other laboratories working with complex heterogeneous samples.
Immunoglobulin light chain amyloid aggregation

Chemical Communications | August 1, 2018 | Volume: 54 | Issue: 76 | Pages: 10664-10674

10.1039/c8cc04396e | PMID 30087961

Light chain (AL) amyloidosis is a devastating, complex, and incurable protein misfolding disease.
Differences in Protein Concentration Dependence for Nucleation and Elongation in Light Chain Amyloid Formation

Biochemistry | January 11, 2017 | Volume: 56 | Issue: 5 | Pages: 757-766

10.1021/acs.biochem.6b01043 | PMID 28074646